Brief: Precigen Says Positive Phase 1 Data For Off-The-Shelf PRGN-2009 Adenoverse Immunotherapy Alone And In Combination With Investigational Checkpoint Inhibitor In Patients With Recurrent/Metastatic HPV-Associated Cancers

Precigen

03/06/2023 17:03

June 3 (Reuters) - Precigen Inc  PGEN.O :
    * PRECIGEN ANNOUNCES POSITIVE PHASE 1 DATA FOR OFF-THE-SHELF
PRGN-2009 ADENOVERSE™ IMMUNOTHERAPY ALONE AND IN COMBINATION
WITH AN INVESTIGATIONAL CHECKPOINT INHIBITOR IN PATIENTS WITH
RECURRENT/METASTATIC HPV-ASSOCIATED CANCERS
    * PRECIGEN INC SAYS PRGN-2009 WAS SAFE AND WELL-TOLERATED
WITH
ONLY GRADE 1 OR 2 TREATMENT RELATED ADVERSE EVENTS
    * PRECIGEN INC SAYS INTERIM CLINICAL DATA PRESENTATION FROM
PHASE
2 MONOTHERAPY ARM IS EXPECTED IN SECOND HALF OF 2023

Source text for Eikon:  ID:nPnbwvggda 
Further company coverage:  PGEN.O 

 ((Reuters.Briefs@thomsonreuters.com;))